Reports Q1 revenue $30.76M, consensus $30.27M. “We continued our successful launch of OJEMDA in 2025 and are energized by the growing impact we are bringing to patients every day,” said Jeremy Bender, chief executive officer of Day One. “This is an exciting time of growth for Day One. We remain focused on creating value at every level of the organization, and we are executing on our objectives with urgency and fiscal discipline.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- DAWN Upcoming Earnings Report: What to Expect?
- Day One Biopharmaceuticals price target lowered to $21 from $24 at BofA
- Promising Outlook for Day One Biopharmaceuticals: Buy Rating Driven by Ojemda’s Market Potential
- Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential